Today: 12 May 2026
Browse Category

NASDAQ:IRWD 2 January 2026 - 5 January 2026

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals shares rose about 1% premarket Monday after Citizens upgraded the stock, citing eased pricing pressure on Linzess. The company last week cut Linzess’s list price by about 50% and forecast 2026 revenue of $450–$475 million. Shares closed up 26.7% Friday at $4.27, with trading volume surging to 85 million. Ironwood remains in a strategic alternatives review and plans a Phase 3 apraglutide trial in 2026.
5 January 2026
··
Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

Ironwood Pharmaceuticals shares jumped 26.7% Friday to $4.27 after the company issued 2026 guidance, forecasting total revenue of $450 million to $475 million and adjusted EBITDA above $300 million. The company expects 2026 Linzess U.S. net sales of $1.125 billion to $1.175 billion after lowering the drug’s list price on Jan. 1. Investors await a fourth-quarter update on the apraglutide Phase 3 trial and strategic review.
4 January 2026
·
AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie shares rose 0.2% to $228.95 after Ironwood Pharmaceuticals, its Linzess partner, raised 2026 U.S. net sales guidance and cut the drug’s list price effective Jan. 1. Ironwood shares jumped 29.5%. Ironwood now expects 2026 Linzess U.S. net sales of $1.125–$1.175 billion, up from 2025’s $860–$890 million forecast. Wall Street trading was muted as investors awaited U.S. labor data and watched for broader drug pricing moves.
2 January 2026
···

Stock Market Today

  • ASX set to dip after budget scraps 50% capital gains tax discount
    May 12, 2026, 5:32 PM EDT. The Australian federal budget removed the 50% capital gains tax (CGT) discount on investments, aiming to correct undercompensation for inflation's impact on shares. This move targets intergenerational housing inequality by shifting investment incentives from property to stocks and new properties. While some investors like Liam Walsh, with $3 million in growth shares, anticipate personal losses, they acknowledge the policy's broader merit. Economists warn that the prior CGT settings favored property wealth accumulation, limiting opportunities for new investors. The reforms are expected to encourage investment decisions driven by economic factors rather than tax avoidance, potentially reshaping Australia's wealth-building landscape.

Latest article

Camtek Stock Falls 16% After Earnings Beat as Margin Pressure and Hot CPI Hit AI Chip Trade

Camtek Stock Falls 16% After Earnings Beat as Margin Pressure and Hot CPI Hit AI Chip Trade

12 May 2026
Camtek shares fell 15.8% to $174.63 despite beating Q1 revenue and adjusted EPS estimates by small margins. Q1 revenue rose 2.5% year over year, but non-GAAP EPS dropped to $0.70 from $0.79 and operating margin narrowed to 25.5%. Management guided Q2 revenue to $129–$131 million and expects second-half revenue to rise over 25%. Broader market pressure followed a hot April CPI and rising Treasury yields.
Oscar Health stock rises in premarket after 2026 revenue outlook; House subpoenas add a fresh risk

Oscar Health Stock Extends Post-Earnings Repricing as Margins Outweigh ACA Risk

12 May 2026
Oscar Health shares rose 7.9% to $23.73 late Tuesday, with volume near 13 million, after posting strong Q1 profit and lower claims costs despite missing revenue estimates. The company’s medical loss ratio fell to 70.5% from 75.4% a year earlier. Membership climbed to 3.17 million. ACA enrollment churn and policy risk remain concerns.
Zebra Technologies stock jumps as Q1 earnings reset the automation recovery trade

Zebra Technologies stock jumps as Q1 earnings reset the automation recovery trade

12 May 2026
Zebra Technologies shares jumped 11.5% to $241.79 after first-quarter sales rose 14.3% to $1.495 billion and non-GAAP EPS hit $4.75. The company raised its 2026 outlook, projecting 10%–14% sales growth and $18.30–$18.70 in non-GAAP EPS. Investors responded to stronger guidance and signs of broader demand across regions and segments.
Go toTop